EVER SUPREME BIO TECHNOLOGY CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2016-12-01
- Employees
- -
- Market Cap
- -
Clinical Trials
7
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 2
2 (28.6%)A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: HLA-G-CAR.BiTE allogeneic γδ T cells
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06150885
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
Phase 2
Recruiting
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Other: Control group
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT06147986
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Phase 1
Recruiting
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: Control group
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT05532943
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
Phase 1
Active, not recruiting
- Conditions
- COVID-19 Infection
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05501418
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04434768
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
- Prev
- 1
- 2
- Next
News
No news found